Dr. Agarwal's Health Care Limited has announced that its Board of Directors will convene on Thursday, May 21, 2026, to consider and approve the Audited Financial Results — both Standalone and Consolidated — for the quarter and year ended March 31, 2026. The announcement was made pursuant to Regulation 29 & 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings and Analyst Conference Call Details

Following the conclusion of the Board meeting, the company will host an Earnings/Analyst Conference Call on the same day to discuss the Annual Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. The call is scheduled from 06:30 P.M. IST to 07:30 P.M. IST. Investors and analysts are requested to dial in 10 minutes ahead of the scheduled start time.

The key details of the conference call are summarised below:

Management Representatives

Dr. Agarwal's Health Care Limited will be represented on the call by the following senior management members:

• Dr. Adil Agarwal – Whole-time Director and Chief Executive Officer
• Mr. Yashwanth Venkat – Chief Financial Officer
• Ms. Aashna Dharia – Head, Investor Relations

International Dial-in Numbers

Participants joining from outside India can use the following international toll-free numbers:

Trading Window Closure

In accordance with the company's Code of Conduct for Prevention of Insider Trading, the Trading Window will remain closed until 48 hours after the announcement of the Financial Results. Further details and corporate announcements are available on the company's official website at https://dragarwals.co.in/dr-agarwals-health-care/#corporate-announcement .

Dr. Agarwal's Health Care Limited has completed the allotment of 1,50,282 equity shares to eligible employees under its Employee Stock Option Scheme 2022. The Nomination and Remuneration Committee of the Board of Directors approved this allotment through a circular resolution dated April 08, 2026.

Share Capital Enhancement

The allotment has resulted in an increase in the company's paid-up equity share capital. The capital structure change is detailed below:

ESOP Exercise Details

The shares were allotted under the Dr. Agarwal's Health Care Limited – Employees Stock Option Scheme 2022 to employees of the company and its subsidiaries. The exercise was completed across multiple tranches with different pricing structures:

Premium Structure

The premium component for each tranche reflects the difference between exercise price and face value:

• Tranche 1: Premium of ₹83.93 per share
• Tranche 2: Premium of ₹128.88 per share
• Tranche 3: Premium of ₹134.00 per share

Regulatory Compliance

The allotment was conducted in compliance with Regulation 10(c) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has informed both BSE Limited and National Stock Exchange of India Limited about this development.

Share Characteristics

The newly allotted equity shares carry the same rights and privileges as existing shares, being ranked pari passu with the company's current equity shares. The shares have been assigned distinctive numbers from 31,68,07,507 to 31,69,57,788 and carry the ISIN INE943P01029 for demat purposes.